Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing

Area of Science:

• Respiratory Medicine
• Clinical Pharmacology

Background:

• Asthma management often involves fixed-dose inhalers.
• Optimizing inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) therapy is crucial for effective asthma control.

Purpose of the Study:

• To compare the efficacy and cost-effectiveness of an adjustable-dosing regimen versus a fixed-dosing regimen of budesonide/formoterol in asthma patients.
• To evaluate the impact of a self-guided management plan on asthma exacerbations and medication use.

Main Methods:

• A randomized, open-label, multicenter study involving 1034 asthma patients.
• Patients received budesonide/formoterol (80/4.5 mcg or 160/4.5 mcg) for four weeks, followed by six months of either adjustable or fixed maintenance dosing.
• Adjustable dosing allowed patients to modify their inhalations based on symptom control, guided by a self-management plan.

Main Results:

• The adjustable-dosing group had fewer patients with exacerbations (6.2% vs. 9.5%, NNT 30, p<0.05).
• Fewer daily inhalations of budesonide/formoterol were used in the adjustable group (2.35 vs. 3.95, p<0.001).
• The adjustable regimen resulted in significant cost savings (Euros 98 over six months, p<0.001) and was well-tolerated.

Conclusions:

• Adjustable maintenance dosing with budesonide/formoterol offers superior asthma control compared to fixed dosing.
• This approach reduces medication use and healthcare costs while maintaining safety and tolerability.